Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


More woe for AspenBio with new AppyScore delay

This article was originally published in Clinica

Executive Summary

AspenBio Pharma's 510(k) application for its troubled appendicitis blood test, AppyScore, looks likely to be delayed again. The company recently finished an expanded pivotal trial and had hoped to file the product with the US FDA in late June. However, it has now reported that it needs to carry out further analysis of the study results, as there was "unexplained variability" between sites. As a result, the Castle Rock, Colorado firm's share price on Nasdaq dropped by 54% on 7 June, closing at $1.57. This is not the first delay for AppyScore: AspenBio first submitted a 510(k) application in July 2009 based on disappointing results from a previous pivotal trial, but had to withdraw it in February and expand the study (, 10 February 2010).

You may also be interested in...

What are the hottest innovations from Israel?

Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.

EuroPCR: St Jude and Philips talk up rival intravascular imaging techs

St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.

EuroPCR: Medtronic's drug-coated balloon keeps rising

A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts